Innate Immune Recognition Enhances Flavivirus Vaccine Efficacy
Innate Immune Recognition Enhances Flavivirus Vaccine Efficacy
批准号:
7905119
负责人:
Gregg N. Milligan
金额:
$59.94万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2012-07-31
关键词:
AddressAnimalsAntibodiesAntibody FormationAntigensB-LymphocytesBone MarrowCD8B1 geneCategoriesCellsChemicalsDefectDendritic CellsDengueDevelopmentDiseaseEncephalitisFlavivirusFlavivirus InfectionsGene ExpressionGenesGenomeHumanImmuneImmune Cell ActivationImmune responseImmunityInfectionInterferon ReceptorInterferon Type IInterferonsLeadLearningLinkMethodsMusNamesNormal CellPathway interactionsPattern recognition receptorProcessProductionRNARepliconResourcesRoleSystemT cell responseT memory cellT-LymphocyteVaccinationVaccinesViralVirionVirusVirus DiseasesWest Nile virusadaptive immunitybasecell typecytokinein vivoinsightlymph nodesmacrophagemembermultidisciplinaryparticlepathogenprotein kinase Rreceptor bindingresponsetooltype I interferon receptoruptakevaccine candidatevaccine efficacyviral RNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Flaviviruses populate the NIAID's Category A, B, and C lists of viruses. Vaccines are urgently needed for multiple flavivirus diseases, notably dengue and West Nile encephalitis. To develop more effective vaccines a comprehensive understanding of how flaviviruses trigger immune responses is needed. To address this need, we developed single-cycle flaviviruses and packaging cell systems that produce them at high titers. These single-cycle viruses include West Nile virus (WNV) -derived viral replicon particles (VRPs) and a WN encephalitis vaccine candidate named Replivax. Both particles encode self-replicating WNV RNA genomes (replicons) deficient in one or more genes required for genome packaging. VRPs and Replivax mimic many aspects of WNV infection (receptor binding, uptake, RNA release, and genome replication). However, VRPs and Replivax cannot produce progeny virions in normal cells, and hence are not pathogenic. Nevertheless, Replivax encodes a protective immunogen, the sub-viral particle (SVP), and has proven to be a remarkably potent vaccine candidate. VRPs can be modified to express marker genes (to allow tracking in vivo), further enhancing their utility. Our single-cycle particles target the draining lymph nodes of mice, where they infect macrophages and induce high levels of type I interferon (IFN), suggesting that IFN is critical for directing the adaptive immune response to our vaccine. However, mice deficient in type I IFN receptors produced antibody responses to Replivax indistinguishable from WT animals, suggesting that IFN was not linking innate and adaptive immunity. In the process of learning how WNV induces IFN, we examined how ex vivo cultures of murine bone marrow-derived dendritic cells responded to WNV VRP infection. These studies showed that protein kinase R (PKR) appeared to be acting as a pattern-recognition receptor (PRR) that triggered IFN synthesis. Further, VRP-inoculated PKR-deficient mice produced lower levels of IFN and lower levels of WNV-specific antibodies than WT mice, indicating that PRR pathways (PRRPs) control both innate and adaptive responses. Based on these studies we hypothesize that: Recognition of Replivax via PRRs results in the engagement of multiple PRRPs, which may act independently, or in concert, to induce innate and adaptive immunity. This hypothesis will be evaluated in 3 specific aims in which we will elucidate the effect of macrophage depletion and deficiencies in specific PRRPs on the 1) innate, 2) humoral, and 3) cellular immune response in mice inoculated with these unique single-cycle flavivirus particles.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cervicovaginal Vaccine Delivery by Novel Pod Intravaginal Rings for Therapeutic Immunization Against HSV-2
-
批准号:10040583
-
项目类别:
-
资助金额:$24.94万
-
财政年份:2020
-
负责人:Gregg N. Milligan
-
依托单位:
Cervicovaginal Vaccine Delivery by Novel Pod Intravaginal Rings for Therapeutic Immunization Against HSV-2
-
批准号:10171554
-
项目类别:
-
资助金额:$19.65万
-
财政年份:2020
-
负责人:Gregg N. Milligan
-
依托单位:
Induction, maintenance, and function of genital tract-resident CD8+ T cells
-
批准号:8975361
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2015
-
负责人:Gregg N. Milligan
-
依托单位:
Induction, maintenance, and function of genital tract-resident CD8+ T cells
-
批准号:9193609
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2015
-
负责人:Gregg N. Milligan
-
依托单位:
Induction, maintenance, and function of genital tract-resident CD8+ T cells
-
批准号:9094547
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2015
-
负责人:Gregg N. Milligan
-
依托单位:
Immunization with a Novel Single Cycle Flavivirus Particle Vector and Antigenic Peptide Nanofibers as a Prime-boost Vaccine Strategy against HSV-2
-
批准号:8873100
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2015
-
负责人:Gregg N. Milligan
-
依托单位:
Innate Immune Recognition Enhances Flavivirus Vaccine Efficacy
-
批准号:7679756
-
项目类别:
-
资助金额:$61.27万
-
财政年份:2009
-
负责人:Gregg N. Milligan
-
依托单位:
Dendritic Cell Targeting Enhances Flavivirus Vaccine Efficacy
-
批准号:7897216
-
项目类别:
-
资助金额:$22.1万
-
财政年份:2007
-
负责人:Gregg N. Milligan
-
依托单位:
Dendritic Cell Targeting Enhances Flavivirus Vaccine Efficacy
-
批准号:7500651
-
项目类别:
-
资助金额:$22.1万
-
财政年份:2007
-
负责人:Gregg N. Milligan
-
依托单位:
Vaccine-elicited genital and neuronal T cell responses
-
批准号:6598960
-
项目类别:
-
资助金额:$36.69万
-
财政年份:2003
-
负责人:Gregg N. Milligan
-
依托单位:
Vaccine-elicited genital and neuronal T cell responses
-
批准号:7033868
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2003
-
负责人:Gregg N. Milligan
-
依托单位:
Vaccine-elicited genital and neuronal T cell responses
-
批准号:6856563
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2003
-
负责人:Gregg N. Milligan
-
依托单位:
Vaccine-elicited genital and neuronal T cell responses
-
批准号:6703076
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2003
-
负责人:Gregg N. Milligan
-
依托单位:
Vaccine-elicited genital and neuronal T cell responses
-
批准号:7224142
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2003
-
负责人:Gregg N. Milligan
-
依托单位:
PROTECTION OF GENITAL MUCOSA AND GANGLIA AGAINST HSV-2
-
批准号:6149883
-
项目类别:
-
资助金额:$17.6万
-
财政年份:1999
-
负责人:Gregg N. Milligan
-
依托单位:
Protection of Genital Mucosa and Ganglia Against HSV-2
-
批准号:6871837
-
项目类别:
-
资助金额:$13.21万
-
财政年份:1999
-
负责人:Gregg N. Milligan
-
依托单位:
Protection of Genital Mucosa and Ganglia Against HSV-2
-
批准号:7188102
-
项目类别:
-
资助金额:$25.06万
-
财政年份:1999
-
负责人:Gregg N. Milligan
-
依托单位:
Protection of Genital Mucosa and Ganglia Against HSV-2
-
批准号:7897647
-
项目类别:
-
资助金额:$24.33万
-
财政年份:1999
-
负责人:Gregg N. Milligan
-
依托单位:
PROTECTION OF GENITAL MUCOSA AND GANGLIA AGAINST HSV-2
-
批准号:6497099
-
项目类别:
-
资助金额:$18.8万
-
财政年份:1999
-
负责人:Gregg N. Milligan
-
依托单位:
PROTECTION OF GENITAL MUCOSA AND GANGLIA AGAINST HSV-2
-
批准号:6349855
-
项目类别:
-
资助金额:$7.44万
-
财政年份:1999
-
负责人:Gregg N. Milligan
-
依托单位:
海外基金